2

3

4

5

FEB

JAN

MAR

6

7

8

9

Increased exports to Japan & other API proportion increased

10

4.6% 28.8%

3.5% 133.1%

11.5% 157.1%

11.5% 139.7%

5.9% 25.9%

4.8% 126.2%

12.9% 149.3%

12.9% 132.9%

11

18.4% -0.7%

TTB -63.1%

TTB -82.3%

TTB -88.0%

12

9.3% 3.9%

26.5% 4.7%

17.2% 3.5%

26.6% 26.3%

-1.2% 4.3%

35.3% -64.1%

-6.0% -8.9%

4.8% 21.5%

13

14

789.3

15

16

17

Diabetes/Obesity

Rare diseases

Cancer

Autoimmune diseases

Others

B Beijing Hanmi

Pre-Clinical Phase 2 Phase 3Phase 1

LAPSInsulin ComboHM14220Diabetes

SANOFI

GBM Stem Cell TherapyHM21001Glioblastoma

AJOU Univ

LAPSTriple AgonistHM15211NASH

LAPSGCG AnalogHM15136Obesity

LAPSGCG AnalogHM15136Congenital Hyperinsulinism

PD-1/CD47BH29XXTargeted Immuno-oncology

B

LAPSASBHM15450Mucopolysaccharidosis

LAPSGLP/GCGHM12525A·JNJ64565111Obesity/Diabetes

JANSSEN

LAPSIns/LAPSInsulin AnalogHM12460A/HM12470Diabetes

Pan-RAF InhibitorBelvarafenibSolid tumors

GENENTECH

PD-1/PD-L1BH2996HTargeted Immuno-oncology

B

EfpeglenatideLAPSExd4 AnalogObesity/Diabetes

SANOFI

EfpegsomatropinLAPShGHGH deficiency

Luminate®

Integrin inhibitor

DMEALLEGRO

BTK InhibitorHM71224Autoimmune disease

Pan-HER InhibitorPoziotinibSolid tumor

SPECTRUM

Rolontis™EflapegrastimNeutropenia

SPECTRUM

Oraxol™Paclitaxel+HM30181ASolid tumor

ATHENEX

PD-1/HER2BH2950Targeted Immuno-oncology

B

INNOVENT

FLT3 InhibitorHM43239

AML

TNF-α/IL-17BH1657Targeted Autoimmune diseases

B

LAPSGLP-2 AnalogHM15912Short Bowel Syndrome

LAPSInsulin148HM12480Diabetes

LAPSGCG ComboHM14320Obesity/Diabetes/NASH

Luminate®

Integrin inhibitorRetinitis Pigmentosa

Oratecan™Irinotecan+HM30181ASolid tumor

Oradoxel™Docetaxel+HM30181ASolid tumor

ATHENEX

ATHENEX

A2AR antagonist

Solid tumor

LSD1 Inhibitor

SCLC, AML

18